Close

Search

Search Menu
Photonics Media Photonics Buyers' Guide Photonics EDU Photonics Spectra BioPhotonics EuroPhotonics Industrial Photonics Photonics Showcase Photonics ProdSpec Photonics Handbook
More News
share
Email Facebook Twitter Google+ LinkedIn Comments

IOPtima Ltd.

BioPhotonics
Aug 2008
IOPtima Ltd. of Ramat Gan, Israel, has completed the three-month follow-up period for its initial human clinical study using the OT134 device. The laser-based therapy enables eye surgeons to operate and reduce internal eye pressure without penetrating the ocular membrane. So far, the results suggest that the laser filtration system may be a viable alternative to current glaucoma therapies.

BiophotonicsIOPtima Ltd.laser filtration systemlaser-based therapyNews & Featureslasers

Comments
Terms & Conditions Privacy Policy About Us Contact Us
back to top
Facebook Twitter Instagram LinkedIn YouTube RSS
©2018 Photonics Media, 100 West St., Pittsfield, MA, 01201 USA, info@photonics.com

Photonics Media, Laurin Publishing
x Subscribe to BioPhotonics magazine - FREE!
We use cookies to improve user experience and analyze our website traffic as stated in our Privacy Policy. By using this website, you agree to the use of cookies unless you have disabled them.